Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Biochip for the diagnosis of Familial Hypercholesterolemia

10.02.2004


Hypercholesterolemia patients now have a new method of diagnosis that enables them to know for sure if they are suffering from Familial Hypercholesteloremia (FH) or not. The new tool, known as Lipochip, is the first biochip for the diagnosis of Familial Hypercholesteloremia (a pathology that affects some 100,000 persons in Spain).



The majority of those currently suffering from FH are not diagnosed as such. It is calculated that less than 30% of them have received a correct diagnosis with the majority receiving inadequate or inappropriate treatment. Moreover, when the illness is diagnosed, it is often too late as the patient a premature cardiovascular event which may be life-threatening.

Lipochip enables the early diagnosis of a large number of patients in a short space of time. In this way, cardiovascular illnesses can be prevented, these pathologies appearing in more than half of the patients affected by FH before 55 years of age. Amongst those between 20 and 39 years of age who suffer from Familial Hypercholesterolemia, mortality due to a coronary pathology is 100 times greater than amongst those without FH.


The importance of early diagnosis of FH with Lipochip lies in this high incidence of level of premature cardiovascular illnesses amongst FH patients. Without the correct diagnosis and treatment, many patients die between 35 and 65 years of age, and seven out of ten will suffer myocardiac attack before their sixtieth birthday. However, with early diagnosis and treatment, the survival rate and quality of life of patients improves, as these coronary events are greatly diminished. This also reduces hospital costs as there are less cardiovascular events amongst patients being suitably diagnosed and treated.

Early detection

Another important aspect, that can only be covered by the use of Lipochip, is the detection of the illness amongst young people who do not have symptoms but who, not being diagnosed early or receiving appropriate treatment, are subject to having an unexpected cardiovascular events. Up to now, the clinical diagnosis of FH has been based on typical clinical signs, on analytical data and on family history of the patient.

Thanks to the use of Lipochip, the illness can be diagnosed with complete reliability, i.e. knowing if the patient is a carrier of one of the mutations responsible for FH, using a small blood sample and in a matter of just a few days. Even in those patients that have a definite clinical diagnosis, the detection of the mutation may have prognostic value, given that some studies back up the hypothesis that the type of mutation may also have an influence on the response to pharmaceutical drugs, and so with the type of mutation determining the treatment.

Lipochip enables the carrying out of a genetic diagnosis of Familial Hypercholesterolemia, and considered to be of the greatest reliability. In this way, the appearance of false positives and false negatives are eliminated, which have arisen up to now using the diagnostic table of MedPed (the international programme of the World Health Organisation). The WHO, by means of this programme, recommended the development of techniques capable of detecting mutations in the LDL receptor gene in order to provide a reliable and early diagnosis of Familial Hypercholesterolemia. The mutations in this gene are the cause FH.

The principle of Lipochip is the capacity of DNA to recognise its complementary sequence.
Basically, it consists of a chemically modified glass surface onto which a large number of genic sequences complementary to each of the mutations have been deposited. To this surface the patient’s sample, marked with a fluorescent molecule, is added. Subsequent illumination with laser enables the identification of which of the points the patient’s blood sample has bonded to with greatest intensity. In this way specific discrimination between a normal patient and one suffering from Familial Hypercholesterolemia is established.

The novelty of this diagnostic tool is that it enables the analysis of thousands of sequences in a differentiated, rapid and reliable manner, unlike the traditional techniques of the independent analysis of each sequence in question, which can take months.

Lipochip has been designed and developed by the Progrenika-Medplant technological support group, based on knowledge provided by Familial Hypercholesterolemia Foundation and the Department of Biochemistry at the University of Zaragoza.


Contact :
Laureano Simón
Progenika S.A.
lsimon@progenika.com
(+34) 944064525

Garazi Andonegi | Basque research
Further information:
http://www.basqueresearch.com/berria_irakurri.asp?Gelaxka=1_1&Berri_Kod=408&hizk=I
http://www.progenika.com

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>